Search

Search Constraints

You searched for: Author/Creator Pan, Y.

Search Results

2. 135P Camrelizumab plus chemotherapy as first-line therapy for NSCLC: A pooled analysis of two randomized phase III trials with extended follow-up. (December 2022)